Processa Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

STATEMENTS OF STOCKHOLDERS' EQUITY

STATEMENTS OF STOCKHOLDERS' EQUITY (USD $)	Series A Preferred Stock	Series B Preferred Stock	Series C Preferred Stock	Series D Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total Stockholders' Equity
Beginning Balance, amount at Dec. 31, 2012	$ 60	$ 150	$ 76		$ 190	$ 5,992,636	$ (3,430,807)	$ 2,562,305
Beginning Balance, shares at Dec. 31, 2012	600,000	1,500,000	760,000		1,900,000
Preferred stock conversion to common, shares	(600,000)	(1,323,000)	(659,000)		6,182,000
Preferred stock conversion to common, value	(60)	(132)	(66)		618	(360)
Stock issued in private placement, shares				727,648
Stock issued in private placement, value				73		2,182,871		2,182,944
Share issuance costs						(84,232)		(84,232)
Stock-based compensation						216,083		216,083
Dividends accrued on Series C shares							(69,096)	(69,096)
Dividends accrued on Series D shares							(68,425)	(68,425)
Beneficial conversion feature on Series D issuance						176,729	(176,729)
Net loss for the period							(3,068,701)	(3,068,701)
Ending Balance, amount at Dec. 31, 2013		18	10	73	808	8,483,727	(6,813,758)	1,670,878
Ending Balance, shares at Dec. 31, 2013		177,000	101,000	727,648	8,082,000
Preferred stock conversion to common, shares		(177,000)	(101,000)	(16,332)	294,332
Preferred stock conversion to common, value		(18)	(10)	(2)	29
Stock issued in private placement, shares				171,987
Stock issued in private placement, value				17		515,946		515,963
Share issuance costs						(6,000)		(6,000)
Stock issued for acquisitions, shares					58,333
Stock issued for acquisitions, value					6	174,994		175,000
Preferred stock conversion to common in private placement, shares				(704,379)	1,207,491
Preferred stock conversion to common in private placement, value				(70)	121	(50)
Inducement premium on preferred stock conversion to common						1,332,376	(1,332,376)
Debt conversion in private placement, shares					1,100,876
Debt conversion in private placement, value					110	2,506,872		2,506,982
Issuance of common stock and warrants, shares					209,324
Issuance of common stock and warrants, value					21	366,303		366,324
Stock-based compensation						231,524		231,524
Dividends accrued on Series C shares							(2,200)	(2,200)
Dividends accrued on Series D shares							(179,430)	(179,430)
Beneficial conversion feature on Series D issuance						51,110	(51,110)
Warrants issued in conjunction with debt offering						455,142		455,142
Net loss for the period							(4,526,250)	(4,526,250)
Ending Balance, amount at Dec. 31, 2014				$ 18	$ 1,095	$ 14,111,944	$ (12,905,124)	$ 1,207,933
Ending Balance, shares at Dec. 31, 2014				178,924	10,952,356